iRadimedIRMD
About: iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Employees: 148
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
75% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 36
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
12% more capital invested
Capital invested by funds: $303M [Q2] → $338M (+$35.1M) [Q3]
4% more funds holding
Funds holding: 137 [Q2] → 142 (+5) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
1.34% less ownership
Funds ownership: 54.5% [Q2] → 53.17% (-1.34%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for IRMD.
Financial journalist opinion
Based on 3 articles about IRMD published over the past 30 days